Nexgen's EGFstable Registered to U.S. CTFA

Published: 2005-03-09 06:56:00

Updated: 2005-03-09 06:56:00

Nexgen Biotechnologies Inc., a domestic venture firm specialized in second generation plant biotechnology, announced that it has made a successful registration of its EGFstable(TM), a novel hEGF (human Epidermal Growth Factor) protein, as an approved cosmetic ingredient to CTFA (Cosmetic, Toiletr...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK